BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat24/7 Wall Street • 08/28/26
Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior NotesAccesswire • 08/28/26
Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthroughReuters • 08/28/26
Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior NotesAccesswire • 08/27/26
Explainer: How the Merck/Moderna cancer vaccine works and possible barriers to wide useReuters • 08/25/26
Moderna Rallies 11%, BioNTech Ticks Up: Is the mRNA Trade Down to One Name?24/7 Wall Street • 08/25/26
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.24/7 Wall Street • 08/25/26
Moderna Sinks 7% as Traders Book Profits on a 392% Year-to-Date Surge; BioNTech Drops 4%, Merck Slips24/7 Wall Street • 08/24/26
Moderna CEO warns China is investing heavily in mRNA as Beijing challenges US in biotechnologyFox Business • 08/24/26
Moderna Is Betting Big on Its Cancer Vaccine. This Is What Wall Street Wants to See.Barrons • 08/24/26